

Pre-Program Activities	Lecture 1 – Viral Hepatitis – the natural history and manifestations of HCV – 60 min Lecture 2 - End Stage Liver Disease: Treatment, Managing Complications and Transplant – 45 min
7:00am	<i>Registration and View Exhibits</i>
7:30 am	Opening Comments and Pre-Test
7:45 am	Hepatitis C: Update on Diagnostics <ul style="list-style-type: none"> • Short recap of key points from Pre-course lecture on viral hepatitis • Screening and diagnostic approaches by cohort • Liver biopsy and newer, non-invasive diagnostic tools Hepatitis C: Update on Treatment <ul style="list-style-type: none"> • AASLD/IDSA Guidelines • Simplified Guidance Case Studies 1 and 2 –HIV/HCV Co-infection; Infections in persons who inject drugs.
8:50 am	Hepatitis B: Epidemiology, Natural History and Testing <ul style="list-style-type: none"> • The epidemiology of the Hepatitis B infection • Efficacies and opportunities in HBV testing and vaccination • The growing relationship between HBV and HDV
9:20 am	Delta Hepatitis and Hepatitis E Update <ul style="list-style-type: none"> • Worldwide perspective and promising research studies • Real world outcome studies on HDV and HEV
9:50 am	Product Theater #1 Break and View exhibits
10:30 am	Anti-viral Therapies for HBV <ul style="list-style-type: none"> • Early detection and treatment approaches • Treating HCC in patients with Hepatitis B • Guidance statements for co-infected patients • Reactivation of HBV
11:00 am	End Stage Liver Disease: Recap and Clinical Case <ul style="list-style-type: none"> • Staging, workup, and diagnosis of cirrhosis • Diagnosing and treating hepatic encephalopathy Liver Transplantation <ul style="list-style-type: none"> • Listing criteria, MELD scores, Exceptions and the transplant process Case Study 3 – Cirrhosis and Encephalopathy
11:25 am	Hepatocellular Carcinoma (HCC) <ul style="list-style-type: none"> • Screening diagnostic serum assays and imaging tests • Diagnosis without histology • Treatment and management options: Ablation, TACE and Surgery
12:00 pm	<i>Luncheon Presentation – Product Theater #2</i>
12:45pm	<i>Dessert and View Exhibits</i>
1:00 pm	Hepatocellular Carcinoma: New Systemic Treatment Options <ul style="list-style-type: none"> • Current FDA-Approved Therapies • New chemotherapy regimens in development and testing • Immunotherapy as the new MoA for HCC Case Study 4 – Diagnosis and Treatment of Hepatocellular Carcinoma
1:40 pm	SARS-COV-2 in Liver Disease <ul style="list-style-type: none"> • Effect of COVID on the liver and in cirrhotic patients • COVID-19 challenges for liver transplant recipients
2:05pm	Primary Sclerosing Cholangitis (PSC) and Primary Biliary Cholangitis <ul style="list-style-type: none"> • Epidemiology of PSC and Ursodiol and Antibiotic Treatments • Predicting outcomes and Improving Survival in PSC patients • Causes and Markers of PBC • Ursodeoxycholic Acid (UDCA) and Obeticholic Acid

2:45 pm	Break & View Exhibits
3:00 pm	NAFLD and NASH <ul style="list-style-type: none"> • Epidemiology, Demographics and Diagnosis • Scoring and Management of Fatty Liver Disease • Treatment options for thrombocytopenia; including alternatives to platelet transfusion. • Staging and Management
3:30 pm	NASH Treatments in Practice and in Development <ul style="list-style-type: none"> • Current therapies for NASH • Lifestyle changes as a therapy • Drugs in clinical development for NASH • NASH Updates from AASLD and EASL
4:15 pm	Closing Comments, Post-test and Wrap-Up Program adjourns at 4:30 pm
Post-program activities	Lecture 3 - Viral Hepatitis Updates: The reemergence of Hepatitis A and Alcoholic Liver Disease – 45 min

Course Directors: Paul J. Pockros, MD - Scripps Clinic
Catherine Frenette, MD – Scripps Center for Cell and Organ Transplantation

Peer Review: Tracy Ander, DO - University of Louisville School of Medicine